Is on-demand treatment effective in patients with severe haemophilia?

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Jiménez-Yuste V
  • Fernández-Fontecha E
  • Pérez R
  • Moreno M
  • Spanish Haemophilia Epidemiological Study Working Group

Abstract

On-demand therapy enables stopping haemorrhages rapidly, reducing joint pain and restoring joint mobility, but does not prevent the beginning and subsequent development of haemophilic arthropathy. The main objective of this study was to identify the clinical and orthopaedic status of severe haemophilic patients with bleeding phenotype receiving on-demand treatment in Spain. We conducted an epidemiological, observational, retrospective study, recruiting 167 patients from 36 centres (92% of them with haemophilia A), median age at enrolment of 35 years. Forty per cent of the patients received a combination of on-demand and short-term prophylaxis regimen; the rest was under on-demand treatment. One hundred and forty-five patients (87%) reported at least one bleeding episode and 22 (13%) of the biologically severe patients had no bleeding phenotype. Seventy-one per cent of the studied population presented established haemophilic arthropathy, reaching 80% if we exclude patients without bleeding phenotype. Forty-three per cent of these patients had one or two joints affected, 28% of them had three or four affected joints, 20% reported five or six affected joints and 9% more than six injured joints. An increase in established haemophilic arthropathy with age was observed. Forty-six patients underwent orthopaedic surgery at least once. These data show that on-demand therapy is not effective in preventing the development of haemophilic arthropathy in severe haemophilic population with bleeding phenotype. Therefore, we suggest that the optimal treatment in these patients should be based on prophylaxis. We recommend analysing the reasons for ending prophylaxis, in case its reinstatement should be necessary.

Datos de la publicación

ISSN/ISSNe:
1351-8216, 1365-2516

HAEMOPHILIA  WILEY-BLACKWELL

Tipo:
Article
Páginas:
738-742
Factor de Impacto:
1,063 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 15

Documentos

  • No hay documentos

Métricas

Filiaciones

Filiaciones no disponibles

Keywords

  • haemophilia; haemophilic arthropathy; on-demand therapy; prophylaxis

Campos de estudio

Proyectos asociados

ESTUDIO ABIERTO DE SEGURIDAD Y SOBRE LA EFICACIA DE REFACTO AF EN PACIENTES NO TRATADOS PREVIAMNTE, EN CONDICIONES ASISTENCALES HABITUALES.

Investigador Principal: ANA ROSA CID HARO

3082B2-4434-WW . 2010

ESTUDIO EN FASE II, CIEGO-SIMPLE, RANDOMIZADO, CONTROLADO CON PLACEBO, PARA ESTUDIAR LA EFICACIA Y LA SEGURIDAD DEL NANOBODY ANTI-FACTOR VON- WILLEBRAND ADMINISTRADO COMO TRATAMIENTO ADYUVANTE EN PACIENTES CON PURPURA TROMBOCITOPENICA TROMBOTICA ADQUIRIDA .

Investigador Principal: JAVIER DE LA RUBIA COMOS

ALX-0681-2.1/10 . 2011

ESTUDIO DE INDUCCION DE INMUNOTOLERANCIA EN PACIENTES CON HEMOFILIA A GRAVE CON INHIBIDOR TRAS FRACASO PREVIO EN INDUCCION DE INMUNOTOLERANCIA UTILIZANDO CONCENTRADOS DE FVIII SIN FACTOR VON WILLEBRAND.

Investigador Principal: SATURNINO HAYA GUAITA

RESIST-EXPERIENCED . 2010

SEGURIDAD Y EFICACIA DE N8 EN LA PREVENCION Y EL TRATAMIENTO A DEMANDA DE EPISODIOS HEMORRAGICOS EN SUJETOS CON HEMOFILIA A . SUBESTUDIO: EFICACIA Y SEGURIDAD DE N8 EN LA PREVENCION Y EL TRATAMIENTO DE LA HEMORRAGIA DURANTE LOS PROCEDIMIENTOS QUIRURGICO S EN SUJETOS CON HEMOFILIA A.

Investigador Principal: ANA ROSA CID HARO

NN7008-3568 . 2010

UN ESTUDIO EUROPEO, NO INTERVENCIONAL, LONGITUDINAL, SOBRE LA CALIDAD DE VIDA EN RELACION CON LA SALUD Y LA IDENTIDFICACION DE LOS HECHOS CLAVES EN LOS CAMBIOS DE LAS CONDICIONES DE VIDA DE PACIENTES CON HEMOFILIA A , DE MODERADA A GRAVE, TRATADOS CON HEL IXATE NEXGEN

Investigador Principal: ANA ROSA CID HARO

CSL-FAC-2009-01 . 2010

ESTUDIO DE LA INCIDENCIA DE HEMARTROSIS EN EL PACIENTE HEMOFÍLICO ADULTO GRAVE CON PROFILAXIS SECUNDARIA.

Investigador Principal: JOSE ANTONIO AZNAR LUCEA

PROFILHEMA

CARACTERIZACIÓN DE LOS INHIBIDORES EN PACIENTES CON DIAGNÓSTICO DE HEMOFILIA ADQUIRIDA

Investigador Principal: JOSE ANTONIO AZNAR LUCEA

SET-INM-2010-01

Cita

Compartir